An Advisory Committee on Food and Drug Administration is planned meet on April 6 to discuss whether there is a need to approve or approve COVID-19 booster doses in the future. The Vaccines and Related Biological Products Advisory Committee will also discuss creating a process for selecting SARS-CoV-2 virus strains to be included in future doses of the vaccines. (The same committee meets each spring to select the flu strains used to produce the flu vaccines for the following fall and winter season.) “Now is the time to discuss the need for future boosters, as we aim to “surely. where COVID-19 becomes a virus just like others such as the flu that we are preparing for, protecting against and treating,” said Dr. Peter Marks, director of the FDA’s Center for Biological Evaluation and Research, in a press release. The FDA said the committee will not take a vote and will not discuss specific product applications. Moderna Inc.
and BioNTech SE
and Pfizer Inc.
have separately asked the regulator to allow the fourth dose of their COVID-19 shots.